Financials
Financial year 2025
Cophar from Zottegem, company number BE0699672084, closed financial year 2025 with a result of € 1.1 million after tax. For that financial year Cophar recorded a gross margin of € 13,880 and equity of € 2 million. Compared with financial year 2024, the result moved from € 783,774 to € 1.1 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 7, 2026.
€ 2 million
▲ 29% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.1 million
▲ 44% vs 2024
Profit after tax over the fiscal year.
€ 8,333
▼ 95% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 680,000 paid out
60 % of the profit went to the shareholders, mostly to NEXT GEN PHARMA (100 % of the shares). That is where the money ends up.
People and assets in 2025
0
Average over the fiscal year, from the social balance sheet.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 3,960
▼ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,284
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 201,409 | € 15,823 | € 31,371 | € 13,880 | ▼ 56% |
| Profit after taxes | € 230,708 | € -4,227 | € 783,774 | € 1,128,657 | ▲ 44% |
| Equity | € 1,453,586 | € 1,449,359 | € 1,553,133 | € 2,001,789 | ▲ 29% |
| Total debts | € 689,101 | € 602,678 | € 1,292,959 | € 49,343 | ▼ 96% |
| Cash | € 69,172 | € 40,805 | € 163,927 | € 8,333 | ▼ 95% |
| Retained profit | € 1,203,586 | € 1,199,359 | € 1,303,133 | € 1,751,789 | ▲ 34% |
| Dividend | € 0 | € 0 | € 680,000 | € 680,000 | |
| Bank debt | € 4,182 | € 0 | € 0 | € 0 | |
| Balance sheet total | € 2,142,687 | € 2,052,037 | € 2,846,091 | € 2,051,133 | ▼ 28% |
Key figures of Cophar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Cophar?
What happened at Cophar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 1.1 million (▲ 44% vs 2024). filed late Source: NBB ↗
- New establishment in Haaltert. KBO
- Start of the company according to the CBE. KBO
In short
From € 230,708 profit in 2022 to € 1.1 million profit in 2025.
Paid € 45,874 in corporate taxes since 2022.
Best year ever: 2025, with € 1.1 million profit.
Paid out € 1.4 million in dividends to the owners in total.
A new publication or filing at Cophar? We notify you, reason included.
Follow CopharDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of NEXT GEN PHARMA comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
CopharBehind Cophar are Rik Coessens and Jeremy Coessens. The shares are held by NEXT GEN PHARMA (100%).
Directors
According to the 2025 annual accounts
Shareholders
NEXT GEN PHARMA · holding of Jeremy Coessens
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Ten Ede 192
9620 Zottegem
Atomveldstraat(De) 8 box 2
9450 Haaltert
Active since 5 July 2018
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0699.672.084
- VAT number
- BE 0699.672.084
- Registered office
- Ten Ede 192, 9620 Zottegem
- Names & denominations
- Cophar
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 5 July 2018
- Peppol
- Active · Active since 4 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige ondersteunende activiteiten in verband met financiële diensten, neg, exclusief verzekeringen en pensioenfondsen